Xiaotong Zhang

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/1886826/publications.pdf

Version: 2024-02-01

759233 752698 50 564 12 20 citations h-index g-index papers 54 54 54 709 docs citations times ranked citing authors all docs

#	Article	IF	CITATIONS
1	Relationship between intestinal flora structure and metabolite analysis and immunotherapy efficacy in Chinese <scp>NSCLC</scp> patients. Thoracic Cancer, 2020, 11, 1621-1632.	1.9	44
2	Management of anlotinibâ€related adverse events in patients with advanced nonâ€small cell lung cancer: Experiences in ALTERâ€0303. Thoracic Cancer, 2019, 10, 551-556.	1.9	42
3	Metaâ€analysis of immuneâ€related adverse events of immune checkpoint inhibitor therapy in cancer patients. Thoracic Cancer, 2020, 11, 2406-2430.	1.9	40
4	Prospective study revealed prognostic significance of responses in leptomeningeal metastasis and clinical value of cerebrospinal fluid-based liquid biopsy. Lung Cancer, 2018, 125, 142-149.	2.0	34
5	Quality of life results from a randomized, double-blinded, placebo-controlled, multi-center phase III trial of anlotinib in patients with advanced non-small cell lung cancer. Lung Cancer, 2018, 122, 32-37.	2.0	32
6	Correlation between total homocysteine and cerebral small vessel disease: A Mendelian randomization study. European Journal of Neurology, 2021, 28, 1931-1938.	3.3	31
7	Multicenter evaluation of a new progastrin-releasing peptide (ProGRP) immunoassay across Europe and China. Clinica Chimica Acta, 2015, 438, 388-395.	1.1	30
8	Prediction of OCT images of short-term response to anti-VEGF treatment for neovascular age-related macular degeneration using generative adversarial network. British Journal of Ophthalmology, 2020, 104, 1735-1740.	3.9	28
9	Relationship between the efficacy of immunotherapy and characteristics of specific tumor mutation genes in nonâ€small cell lung cancer patients. Thoracic Cancer, 2020, 11, 1647-1654.	1.9	18
10	Penetration of the blood–brain barrier by avitinib and its control of intra/extra-cranial disease in non-small cell lung cancer harboring the T790M mutation. Lung Cancer, 2018, 122, 1-6.	2.0	17
11	Genomic characteristics of driver genes in <scp>Chinese</scp> patients with nonâ€small cell lung cancer. Thoracic Cancer, 2021, 12, 357-363.	1.9	15
12	Abivertinib in patients with T790Mâ€positive advanced NSCLC and its subsequent treatment with osimertinib. Thoracic Cancer, 2020, 11, 594-602.	1.9	14
13	Association between lipoprotein(a) concentration and the risk of stroke in the Chinese Han population: a retrospective case-control study. Annals of Translational Medicine, 2020, 8, 212-212.	1.7	14
14	Blood eosinophil count-guided corticosteroid therapy and as a prognostic biomarker of exacerbations of chronic obstructive pulmonary disease: a systematic review and meta-analysis. Therapeutic Advances in Chronic Disease, 2021, 12, 204062232110287.	2.5	13
15	Clinical recommendations on diagnosis and treatment of immune checkpoint inhibitorâ€induced renal immuneâ€related adverse events. Thoracic Cancer, 2020, 11, 1746-1751.	1.9	11
16	Opportunistic infections complicating immunotherapy for nonâ€small cell lung cancer. Thoracic Cancer, 2020, 11, 1689-1694.	1.9	11
17	Clinical characteristics and management of immune checkpoint inhibitorâ€related pneumonitis: A singleâ€institution retrospective study. Cancer Medicine, 2021, 10, 188-198.	2.8	11
18	High Level of Uromodulin Increases the Risk of Hypertension: A Mendelian Randomization Study. Frontiers in Cardiovascular Medicine, 2021, 8, 736001.	2.4	11

#	Article	IF	CITATIONS
19	Real-world outcomes of teriflunomide in relapsing–remitting multiple sclerosis: a prospective cohort study. Journal of Neurology, 2022, 269, 4808-4816.	3.6	11
20	Lacune and Large Perivascular Space: Two Kinds of Cavities Are of Different Risk Factors and Stroke Risk. Cerebrovascular Diseases, 2020, 49, 522-530.	1.7	10
21	Successful treatment of pyrotinib for bone marrow metastasis induced pancytopenia in a patient with nonâ€smallâ€cell lung cancer and <scp><i>ERBB2</i></scp> mutation. Thoracic Cancer, 2020, 11, 2051-2055.	1.9	10
22	Histologic transformation of lung cancer during pembrolizumab therapy: A case report. Thoracic Cancer, 2020, 11, 793-796.	1.9	10
23	Opportunistic bowel infection after corticosteroid dosage tapering in a stage IV lung cancer patient with tislelizumabâ€related colitis. Thoracic Cancer, 2020, 11, 1699-1702.	1.9	8
24	Nimotuzumab combined with chemotherapy as firstâ€line treatment for advanced lung squamous cell carcinoma. Thoracic Cancer, 2018, 9, 1056-1061.	1.9	7
25	<p>NLCIPS: Non-Small Cell Lung Cancer Immunotherapy Prognosis Score</p> . Cancer Management and Research, 2020, Volume 12, 5975-5985.	1.9	7
26	A phase III, randomized, double-blind, controlled trial of carboxyamidotriazole plus chemotherapy for the treatment of advanced non-small cell lung cancer. Therapeutic Advances in Medical Oncology, 2020, 12, 175883592096584.	3.2	7
27	Marked elevation of creatine phosphokinase alone caused by sintilimab - beware of hypothyroid myopathy. European Journal of Cancer, 2020, 128, 57-59.	2.8	7
28	The ability of avitinib to penetrate the blood brain barrier and its control of intra-/extra- cranial disease in patients of non-small cell lung cancer (NSCLC) harboring EGFR T790M mutation Journal of Clinical Oncology, 2017, 35, e20613-e20613.	1.6	7
29	Re-biopsy status among Chinese non-small-cell lung cancer patients who progressed after icotinib therapy. OncoTargets and Therapy, 2018, Volume 11, 7513-7519.	2.0	6
30	A validated ultra-HPLC–MS/MS method for determination of honokiol in human plasma and its application to a clinical pharmacokinetic study. Bioanalysis, 2019, 11, 1085-1098.	1.5	5
31	Singleâ€center study to determine the safety and efficacy of CTâ€707 in Chinese patients with advanced anaplastic lymphoma kinaseâ€rearranged nonâ€smallâ€cell lung cancer. Thoracic Cancer, 2020, 11, 1216-1223.	1.9	5
32	Non-motor Symptoms in Chinese Patients With Isolated Generalized Dystonia: A Case–Control Study. Frontiers in Neurology, 2020, 11, 209.	2.4	5
33	Effects of laser debonding treatment on the optical and mechanical properties of all-ceramic restorations. Lasers in Medical Science, 2021, 36, 1497-1504.	2.1	5
34	Second primary tumor after immune checkpoint inhibitor therapy: A case report. Thoracic Cancer, 2022, , .	1.9	5
35	Clinical characteristics and prognostic model for extensiveâ€stage small cell lung cancer: A retrospective study over an 8â€year period. Thoracic Cancer, 2022, 13, 539-548.	1.9	5
36	<p>Successful treatment with osimertinib and its subsequent resistance mechanism in a patient with non-small-cell lung cancer harboring acquired EGFR T790M mutation after recovery from AC0010-induced interstitial lung disease</p> . OncoTargets and Therapy, 2019, Volume 12, 5545-5549.	2.0	4

3

#	Article	IF	CITATIONS
37	Influenza in hospitalised patients with malignancy: a propensity score matching analysis. ESMO Open, 2020, 5, e000968.	4.5	4
38	Predictive Value of Echocardiographic Strain for Myocardial Fibrosis and Adverse Outcomes in Autoimmune Diseases. Frontiers in Cardiovascular Medicine, 2022, 9, 836942.	2.4	4
39	A continuous responder algorithm to optimize clinical management of small-cell lung cancer with progastrin-releasing peptide as a simple blood test. Tumor Biology, 2020, 42, 101042832095860.	1.8	3
40	Successful treatment of pulmonary inflammatory myofibroblastic tumor with platinumâ€pemetrexed: The first report of two cases. Thoracic Cancer, 2020, 11, 2339-2342.	1.9	3
41	Leptomeningeal enhancement in magnetic resonance imaging predicts poor prognosis in lung adenocarcinoma patients with leptomeningeal metastasis. Thoracic Cancer, 2022, 13, 1059-1066.	1.9	2
42	Differential Regulation of the Immune System in Peripheral Blood Following Ischemic Stroke. BioMed Research International, 2022, 2022, 1-15.	1.9	2
43	Treatment with or without bevacizumab as a firstâ€line and maintenance therapy for advanced nonâ€squamous nonâ€small cell lung cancer: A retrospective study. Thoracic Cancer, 2020, 11, 1869-1875.	1.9	1
44	Myocarditis in patients treated with anti–programmed death-1/programmed death ligand 1 therapy Journal of Clinical Oncology, 2021, 39, e14579-e14579.	1.6	0
45	The role of epidermal growth factor receptor mutations (EGFRm) in NSCLC with leptomeningeal metastasis: A prospective observational study Journal of Clinical Oncology, 2015, 33, e19070-e19070.	1.6	O
46	Rebiopsy status among non-small cell lung cancer patients after Icotinib therapy in China Journal of Clinical Oncology, 2018, 36, e21146-e21146.	1.6	0
47	<i>ERBB2</i> mutation profiling with next-generation sequencing (NGS) in solid tumors Journal of Clinical Oncology, 2018, 36, e24264-e24264.	1.6	O
48	Influenza in hospitalized cancer patients: A propensity score matching analysis Journal of Clinical Oncology, 2020, 38, 170-170.	1.6	0
49	Response to letter to the editor by Zhang et al European Journal of Neurology, 2022, , .	3.3	O
	Efficacy and cafety of campalizyman combined with chamatherapy (irinotecan combined with) Ti ETO 0.0.0 graf	RT /Overlag	sh 10 Tf 50 227

Efficacy and safety of camrelizumab combined with chemotherapy (irinotecan combined with) Tj ETQq0 0 0 rgBT /Overlock 10 Tf 50 227 1.6 0 small cell lung cancer: A phase II study.. Journal of Clinical Oncology, 2022, 40, 8573-8573.